Generate Biomedicines (GENB) PE Ratio: History & Chart

Generate Biomedicines, Inc.(GENB)

Biotechnology · Somerville, MA

$13.99+0.08 (+0.58%)

Delayed quote: Oct 6, 2026, 12:35 PM EDT

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Somerville, MA

312 employees

generatebiomedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael T. Nally

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Generate Biomedicines, Inc. (GENB)	$1.79B	N/A	N/A	N/A	N/A
Alignment Healthcare, Inc. (ALHC)vs ›	$1.80B	46.52	147.35	147.35	147.35
Absci Corporation (ABSI)vs ›	$1.79B	N/A	N/A	N/A	N/A
Novocure Ltd (NVCR)vs ›	$1.81B	N/A	1067.41	1002.04	1002.04
LeMaitre Vascular, Inc. (LMAT)vs ›	$1.82B	27.89	37.26	45.15	45.92
Azenta, Inc. (AZTA)vs ›	$1.83B	N/A	61.77	49.90	40.42
Surgery Partners, Inc. (SGRY)vs ›	$1.76B	N/A	7340.14	7340.14	7340.14
Novavax, Inc. (NVAX)vs ›	$1.84B	N/A	3.65	3.65	3.65
Astrana Health, Inc. (ASTH)vs ›	$1.85B	45.75	79.20	49.35	42.48
Palvella Therapeutics, Inc. (PVLA)vs ›	$1.86B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PE RATIO

TTM

Generate Biomedicines, Inc. (GENB)

$1.79B

N/A

Alignment Healthcare, Inc. (ALHC)vs ›

$1.80B

46.52

147.35

Absci Corporation (ABSI)vs ›

$1.79B

N/A

Novocure Ltd (NVCR)vs ›

$1.81B

N/A

1067.41

1002.04

LeMaitre Vascular, Inc. (LMAT)vs ›

$1.82B

27.89

37.26

45.15

45.92

Azenta, Inc. (AZTA)vs ›

$1.83B

N/A

61.77

49.90

40.42

Surgery Partners, Inc. (SGRY)vs ›

$1.76B

N/A

7340.14

Novavax, Inc. (NVAX)vs ›

$1.84B

N/A

3.65

Astrana Health, Inc. (ASTH)vs ›

$1.85B

45.75

79.20

49.35

42.48

Palvella Therapeutics, Inc. (PVLA)vs ›

$1.86B

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

GENB PE Ratio Metrics

GENB Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics